Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 09:59AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.26 Insider Own46.15% Shs Outstand41.03M Perf Week-8.45%
Market Cap28.76M Forward P/E- EPS next Y-0.99 Insider Trans-18.01% Shs Float22.16M Perf Month-6.61%
Income-47.92M PEG- EPS next Q-0.29 Inst Own36.72% Short Float1.45% Perf Quarter-70.88%
Sales10.09M P/S2.85 EPS this Y9.56% Inst Trans-0.35% Short Ratio0.24 Perf Half Y-55.76%
Book/sh1.86 P/B0.37 EPS next Y11.54% ROA-50.55% Short Interest0.32M Perf Year-65.57%
Cash/sh2.34 P/C0.30 EPS next 5Y- ROE-66.10% 52W Range0.68 - 5.95 Perf YTD-76.14%
Dividend Est.- P/FCF- EPS past 5Y-22.95% ROI-60.47% 52W High-88.25% Beta2.50
Dividend TTM- Quick Ratio4.18 Sales past 5Y0.00% Gross Margin98.18% 52W Low3.01% ATR (14)0.17
Dividend Ex-Date- Current Ratio4.18 EPS Y/Y TTM35.64% Oper. Margin-515.34% RSI (14)23.83 Volatility6.73% 7.31%
Employees29 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin-474.96% Recom2.43 Target Price4.20
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q48.72% Payout- Rel Volume0.18 Prev Close0.71
Sales Surprise86.74% EPS Surprise43.11% Sales Q/Q- EarningsMar 13 AMC Avg Volume1.33M Price0.70
SMA20-8.44% SMA50-76.24% SMA200-69.31% Trades Volume27,989 Change-1.02%
Date Action Analyst Rating Change Price Target Change
Mar-14-24Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $2
Mar-14-24Downgrade Leerink Partners Outperform → Market Perform $9 → $2
Mar-14-24Downgrade Ladenburg Thalmann Buy → Neutral
Mar-14-24Downgrade H.C. Wainwright Buy → Neutral
Mar-14-24Downgrade Guggenheim Buy → Neutral
Feb-21-24Initiated Guggenheim Buy $10
Dec-17-21Initiated Oppenheimer Outperform $15
Dec-10-21Initiated The Benchmark Company Speculative Buy $7
Nov-16-21Downgrade SVB Leerink Outperform → Mkt Perform
Jul-19-21Initiated H.C. Wainwright Buy $30
Mar-27-24 12:00PM
Mar-21-24 10:20AM
Mar-14-24 08:28AM
Mar-13-24 05:33PM
04:01PM Loading…
Jan-30-24 04:05PM
Jan-22-24 08:00AM
Jan-05-24 08:00AM
Jan-04-24 08:00AM
Nov-13-23 04:05PM
Nov-02-23 04:05PM
Oct-18-23 08:00AM
Aug-28-23 04:00PM
Aug-14-23 04:00PM
12:00PM Loading…
Jul-24-23 12:00PM
Jun-12-23 04:00PM
May-25-23 08:00AM
May-24-23 04:05PM
May-22-23 09:30AM
May-16-23 06:18AM
May-15-23 08:00AM
May-04-23 04:05PM
May-02-23 04:05PM
Mar-31-23 12:00PM
Mar-16-23 04:00PM
Feb-28-23 04:05PM
Feb-23-23 10:43AM
Feb-10-23 08:00AM
Feb-09-23 08:00AM
04:05PM Loading…
Feb-01-23 04:05PM
Jan-31-23 09:55AM
Jan-09-23 08:05AM
Jan-06-23 05:54PM
Jan-05-23 04:00PM
Nov-16-22 01:13PM
Nov-10-22 04:01PM
Oct-26-22 04:05PM
Aug-30-22 04:05PM
Aug-10-22 04:05PM
Jun-01-22 04:01PM
May-31-22 08:00AM
May-11-22 04:01PM
May-03-22 04:05PM
Apr-11-22 08:00AM
Mar-14-22 04:05PM
Mar-01-22 04:05PM
Feb-03-22 04:05PM
Jan-24-22 08:00AM
Jan-19-22 09:38PM
Jan-05-22 08:00AM
Dec-31-21 01:50PM
Dec-17-21 07:27AM
Dec-14-21 10:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
Sep-29-21 01:06PM
Sep-07-21 04:05PM
Aug-25-21 09:00AM
Aug-11-21 08:55AM
Aug-10-21 04:05PM
Jul-23-21 10:14AM
Jul-07-21 11:38AM
Jun-24-21 08:07AM
Jun-21-21 08:03AM
May-24-21 08:01AM
May-13-21 04:05PM
May-12-21 04:05PM
Mar-22-21 04:05PM
Mar-17-21 08:00AM
Mar-02-21 08:00AM
Feb-17-21 04:05PM
Jan-12-21 05:10AM
Jan-06-21 08:00AM
Dec-17-20 04:05PM
Nov-18-20 04:05PM
Nov-04-20 04:05PM
Oct-16-20 07:38PM
Oct-14-20 04:05PM
Oct-09-20 03:49PM
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerMar 21 '24Sale0.75465,021350,9512,550,000Mar 25 09:45 PM
Novo Holdings A/S10% OwnerMar 20 '24Sale0.73359,979264,0813,015,021Mar 20 08:56 PM
Novo Holdings A/S10% OwnerMar 19 '24Sale0.76593,000447,7153,375,000Mar 20 08:56 PM
Novo Holdings A/S10% OwnerMar 18 '24Sale0.77842,020647,0083,968,000Mar 20 08:56 PM
Novo Holdings A/S10% OwnerMar 14 '24Sale0.891,912,3161,698,9024,810,020Mar 18 09:14 PM
Gharib Samir M.President & CFODec 15 '23Option Exercise0.00112,2500204,403Dec 18 08:16 PM
Charlton Ralph William IIIChief Medical OfficerDec 15 '23Option Exercise0.0031,750056,992Dec 18 08:17 PM
Szwarcberg Javier B.Chief Executive OfficerDec 15 '23Option Exercise0.00111,0000145,705Dec 18 08:15 PM